BB: 2,25x52,75 Size: ≤5 Type: Nonneoplastic

Gastroenterology powered by AI


A game changer in CRC prevention

Research¹ shows that for every per cent increase in adenoma detection, there is a 3 per cent decrease in the occurrence of Colorectal Cancer (CRC), the third most prevalent cancer worldwide, and one of the deadliest.
In this reality, it is no surprise that colonoscopy aided by Artificial Intelligence (AI) and Machine Learning (ML) technologies, which power diagnostic capabilities, and significantly improve clinical decision-making, has become the new standard in high-performing gastroenterology clinics.

The Magentiq Eye difference

Dedicated to the use of advanced technologies to transform procedure performance in the gastroenterology field,
we offer an incomparable combination of efficiency and economic value.






software updates

Fast ROI

business model

Read more

A new benchmark for AI aided colonoscopy

With more than 65,000,000 frames processed, analyzed and tagged over the course of seven years, and validation from a comprehensive study covering more than 950 patients in 10 centers across the globe, our outstanding detection and analysis capabilities are setting new standards.

0 % apc
Adenoma Per Colonoscopy
0 % amr
Adenoma Miss Rate
0 % adr
Adenoma Detection Rate
0 % ssapc
Sessile Serrated APC
View study

Validated by
leading hospitals & clinics

What they say about us

MAGENTIQ-COLO™ is easy to use and adds to quality in the procedure room. By using such AI products, we found in a recent study that less polyps were missed, the ADR increased, and more lives are potentially saved.

Prof. Peter Siersema, MD, Ph.D
Senior gastroenterologist & researcher, Erasmus MC, Rotterdam, The Netherlands & Editor-in-Chief, Endoscopy Journal

I’m very pleased with the MAGENTIQ-COLO™ product. The system fits extremely well to the gastroenterology clinics and assists the doctors during colonoscopy. Thanks to the AI detection more polyps can be detected.

Univ.-Prof. Dr. med. Helmut Neumann
Internationally recognized internist & gastroenterologist

MAGENTIQ EYE’s clinical study which Hadassah took part in, is (to the best of my knowledge), the largest randomized, blinded, international, multi center control trial ever done on AI and polyp detection. It sets new standards of colonoscopy performance, with a 37% relative increase in APC, a 26% relative increase in ADR, and a 48% relative decrease in AMR. 

Dr. Harold Jacob, MD
Director of Gastrointestinal Endoscopy at Hadassah University Medical Center

Public systems investing in mass screening are concerned with the quality of colonoscopy, but with MAGENTIC COLO they can guarantee that the “worst” quality colonoscopy achieves the same level of accuracy as the best. This is not only life saving but also reduces the financial burden of transitioning into mass screening from about 10 years,  to between 2-6. This is a game changer.

Jen Kees Dunning
Healthcare Consultant, Netherlands

Magentiq Eye’s AI product is very helpful in endoscopy and their service is excellent. The cooperation with Magentiq Eye during the pivotal clinical study was great.

Dr. Marc Landsman, MD
Senior Internist & Gastroenterologist and Fellowship Program Director, MetroHealth Medical Center, Ohio
BB: 2,25x52,75 Size: Type:

HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market

The companies expect to formalize an agreement as a first step in this partnership, by which PENTAX Medical will distribute the MAGENTIQ-COLO™ AI-assisted lesion detection device in the U.S.A. beginning October 1st, 2024. 

Open PR

Live demo request

To schedule an on site live demo and try MAGENTIQ COLO, please enter your contact information
Demo Request

What’s new

See all
CAD Improves Multiple Colonoscopy Metrics in International Trial by Caroline Helwick, Gastroenterology & Endoscopy News
A multinational trial and subtrial have added to the growing body of evidence supporting the inclusion of artificial intelligence in…
HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market by Hoya Group / Pentax Medical / Magentiq Eye, press release
AI-Aided Colonoscopy Technology: Dror Zur from Magentiq Eye in a Dialogue Exchange with PharmaShots by Saurabh Chaubey, PharmaShots
Shots:  * Dror Zur, CEO and Founder of Magentiq Eye in a stimulating conversation with PharmaShots talks about the Lancet Digital Health Study journal…
The Incrementalist: AI Revolution in Gastroenterology with Dror Zur, CEO at Magentiq Eye by Dr. Nick van Terheyden, Healthcare NOW Radio Podcast Network
Host Dr. Nick van Terheyden aka Dr. Nick, discusses AI Revolution in Gastroenterology with Dror Zur, CEO at Magentiq Eye.…
The financial benefits of improving the quality of colonoscopy by Marketing, MAGENTIQ EYE
As the medical community recognizes the transforming impact of AI on colonoscopy diagnostic capabilities and the prevention of colorectal cancer,…
Is Artificial Intelligence the future of colonoscopy? by Marketing, MAGENTIQ EYE
We spoke to Dr. Harold Jacob. MD, Director of Gastrointestinal Endoscopy at Hadassah University Medical Center, and one of the first gastroenterologists to…